Few population-based investigations have quantified CVD mortality during, shortly after, and for two decades after TC diagnosis in the era of cisplatin-based chemotherapy.
READ FULL ARTICLE
From Ascopubs
Publish Date
Chemo testicular nonseminoma may increase risk of short-term CVD death
the Oncology Nurse Advisor take:
Patients with testicular nonseminoma have significantly increased cardiovascular disease mortality after chemotherapy but not surgery, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
Previous research from the 1960s has shown that long-term survivors of testicular cancer who were treated with chemotherapy have increased risks of incidence cardiovascular disease, but there is a lack of data on whether treatment increases cardiovascular mortality during, shortly after, and for two decades after diagnosis in a time where most patients with testicular cancer receive cisplatin-based regimens.
For the study, researchers analyzed data from 15,006 patients with testicular nonseminoma from the Surveillance, Epidemiology, and End Results (SEER) database. Of those, 6,909 initially received chemotherapy and 8,097 initially underwent surgery without radiation.
Results showed that cardiovascular disease mortality was significantly increased after chemotherapy but not surgery. Researchers found that increased cardiovascular disease mortality was limited to the first year after testicular cancer diagnosis.
The authors conclude that the increased short-term risk of cardiovascular disease death should be investigated further in analytic studies.
